Tonya Dowd

WORK HISTORY

EDUCATION

SKILLS

ABOUT TONYA DOWD

I am a proven executive leader with more than 25 years of expertise in reimbursement, health economics, market access, and corporate development across the global medtech ecosystem. Over the course of my career, I have built, scaled, and led high-performing market access organizations for startups, mid-size companies, and Fortune 100 enterprises—successfully guiding breakthrough medical technologies from concept through commercialization. I currently serve as Executive Vice President of Reimbursement, Health Economics, Market Access, and Corporate Development at PRIA Healthcare, where I drive enterprise strategy, M&A initiatives, service-line expansion, and commercial planning for more than 90 medtech innovators. Previously, I founded and led the Reimbursement Health Economics and Market Access (RHEMA) division at MCRA (now IQVIA), where I expanded cross-functional capabilities in strategic product planning, HEOR, payer engagement, pricing, evidence strategy, and clinical reimbursement. Earlier in my career, I held leadership and consulting roles at Johnson & Johnson, EndoCare, and Quorum Consulting (now Guidehouse), as well as with multiple early-stage medtech companies. I have secured coding, coverage, and payment for first-in-category technologies; overturned negative payer assessments; developed novel payment pathways; and guided dozens of startups through the complexities of U.S. and global reimbursement. I am widely recognized as a trusted industry advisor and thought leader. I serve as a judge and mentor for MedTech Innovator, a mentor for the CDL Neuro program, and a guest speaker for leading innovation programs including Stanford Biodesign, UCLA Biodesign, Northwestern, Purdue, and NYU. I am also a Scientific Advisory Board Member for the ISCTR and a contributing author to the society’s textbook on translational cardiovascular device development. With deep cross-therapeutic expertise spanning cardiovascular, neurology, urology, orthopedics, oncology, ENT, bariatrics, digital health, and AI-enabled technologies, I bring exceptional strategic clarity and commercialization insight to early-stage medtech teams. I am known for aligning clinical, regulatory, evidence, and payer strategies to accelerate adoption, maximize enterprise value, and reduce commercialization risk. I hold a Master of Public Health in Healthcare Management and Policy from UCLA and a BA in Health Policy from the University of Michigan.